Injection sites for retatrutide follow the same subcutaneous principles used for other injectable peptide therapies, though specific guidance must come from your clinical trial protocol. Retatrutide is an investigational triple agonist targeting GIP, GLP-1, and glucagon receptors, currently under evaluation for obesity and type 2 diabetes. It has not yet received MHRA marketing authorisation, so there is no approved Summary of Product Characteristics. This article outlines best-practice subcutaneous injection technique — covering site selection, rotation, skin preparation, sites to avoid, storage, and sharps disposal — to support safe participation in retatrutide clinical trials.

Commonly Used Injection Sites for Retatrutide

Retatrutide is injected subcutaneously into the abdomen (at least 5 cm from the navel), the anterolateral mid-thigh, or the outer upper arm, with all site guidance governed by the clinical trial protocol.

Retatrutide is an investigational triple agonist targeting GIP, GLP-1, and glucagon receptors, currently under clinical evaluation for the management of obesity and type 2 diabetes. It does not yet hold a marketing authorisation from the MHRA, and there is no approved Summary of Product Characteristics (SmPC). All guidance on administration, injection sites, and storage must therefore come from the clinical trial protocol, the Investigational Medicinal Product (IMP) label, and the instructions for use (IFU) supplied with your specific device. The information below reflects general best practice for subcutaneous injection technique and should be read alongside — not instead of — the instructions provided by your trial team.

Retatrutide is administered subcutaneously — that is, into the fatty tissue just beneath the skin, not into muscle. The three body areas most commonly used for subcutaneous injections of this type are:

• The abdomen — the area around the stomach, at least 5 cm away from the navel

• The front of the thigh (anterolateral, mid-thigh) — the outer-front portion of either thigh

• The outer upper arm — the fatty area of the upper arm (usually easier when administered by a carer or healthcare professional)

These areas are preferred because they contain sufficient subcutaneous adipose tissue for reliable drug absorption. The abdomen is generally the most accessible site for self-injection. The thighs offer a practical alternative, particularly for those who find abdominal injections uncomfortable. Always inject into subcutaneous fat — if you are unsure whether you are reaching the correct tissue layer, speak to your trial nurse or healthcare team. As retatrutide is still in clinical development, site recommendations may be refined as further data become available; follow your trial protocol at all times.

How to Rotate Injection Sites Safely

Rotate injection sites with every dose, moving at least 1–2 cm between points, to prevent lipohypertrophy and maintain consistent drug absorption.

Rotating injection sites with every dose is a fundamental aspect of safe subcutaneous injection practice. Repeatedly injecting into the same spot can lead to lipohypertrophy — a build-up of fatty, fibrous tissue beneath the skin — which can impair drug absorption and reduce the predictability of the medication's effect. Consistent site rotation helps preserve healthy tissue and supports more stable pharmacokinetics.

A structured rotation approach is strongly recommended:

• Rotate with every dose — do not use the same spot twice in succession

• Divide each injection area into a grid of smaller zones, moving systematically from one zone to the next with each injection

• Allow at least 1–2 cm between injection points within the same region

• Alternate between body areas in line with your trial or device instructions — for example, using the abdomen for one dose and the thighs for the next

• Keep a simple log or use a rotation chart to track where the last injection was given

Examine your injection sites regularly. If you notice any areas of hardened, lumpy, or thickened skin — signs of lipohypertrophy — avoid those areas entirely until the tissue has recovered, and report the change to your healthcare provider or trial nurse. Injecting into affected tissue can significantly alter how the medication is absorbed.

For patients participating in clinical trials of retatrutide, the trial team will provide detailed rotation guidance as part of the study protocol. Adhering to this guidance supports both your safety and the integrity of the clinical data being collected.

Further information on lipohypertrophy and site rotation is available from Diabetes UK and the Forum for Injection Technique UK (FIT UK).

Preparing the Skin and Administering the Injection

Wash hands thoroughly, use a new sterile needle for each injection, clean the skin with an alcohol swab, allow it to dry, then insert the needle at 90 degrees (or 45 degrees if slim) and inject slowly.

Correct preparation before administering a subcutaneous injection reduces the risk of infection and ensures the medication is delivered effectively. Before each injection, wash your hands thoroughly with soap and water for at least 20 seconds and dry them completely. Gather all necessary equipment — the pre-filled pen or syringe, a new sterile needle if required, alcohol swabs, and a sharps disposal container.

Important reminders before you begin:

• Always use a new, sterile needle for each injection — never reuse needles

• Never share your pen, syringe, or needles with anyone else, even if the needle is changed

• Follow the device IFU for your specific pen or syringe, including any priming steps and dose-setting instructions

Follow these steps for safe administration:

1. Inspect the medication — Check the solution is clear and colourless or pale yellow, with no visible particles. Do not use if the solution appears cloudy, discoloured, or contains floating matter.
2. Prime the device if required — Some injection pens require priming before first use or after attaching a new needle. Follow your device IFU carefully.
3. Clean the skin — Wipe the chosen injection site with an alcohol swab and allow it to dry fully for at least 10–15 seconds. Injecting into wet skin can cause stinging and may introduce contaminants.
4. Pinch the skin if appropriate — Gently pinch a fold of skin between your thumb and forefinger to lift the subcutaneous tissue away from the muscle beneath. This is particularly important if you are slim or using a longer needle.
5. Insert the needle — For most adults using a 4–6 mm needle, insert at 90 degrees. If you are slim or using a longer needle, a 45-degree angle may be advised. Always follow the angle specified in your device IFU or by your trial team.
6. Inject slowly and steadily — Depress the plunger at a controlled pace, then hold the needle in place for approximately 10 seconds (or as specified in your device IFU) before withdrawing, to ensure the full dose is delivered.

After removing the needle, apply gentle pressure with a clean swab — do not rub, as this may cause bruising or irritation. Never recap a used needle by hand.

The NHS and FIT UK provide authoritative patient-facing guidance on subcutaneous injection technique, needle length, and angle selection.

Sites to Avoid and When to Seek Medical Advice

Avoid injecting into broken, infected, or scarred skin, areas of lipohypertrophy, or within 5 cm of the navel; seek urgent medical advice if you experience signs of infection, persistent swelling, or suspected anaphylaxis.

Certain areas of the body are unsuitable for subcutaneous injection and should always be avoided. Injecting into inappropriate sites can lead to poor drug absorption, increased pain, bruising, or more serious complications such as inadvertent intramuscular injection or nerve damage.

Avoid injecting into:

• Areas of broken, irritated, or sunburned skin

• Sites with bruising, swelling, or active infection

• Scar tissue or stretch marks, which may impair absorption

• Moles, warts, or skin lesions

• The area directly around the navel (within 5 cm)

• Waistbands or areas subject to friction from clothing

• Any site showing signs of lipohypertrophy (hardened, lumpy, or thickened skin)

Mild injection site reactions — such as temporary redness, minor swelling, or slight itching — are relatively common with subcutaneous injectables and usually resolve within a few hours to days.

Contact your GP, trial nurse, or healthcare team if you experience:

• Persistent redness, warmth, or swelling at the injection site lasting more than 48–72 hours

• Signs of infection, including pus, increasing pain, or fever

• A hard lump or significant skin thickening that does not resolve

• Severe allergic reactions, including rash, difficulty breathing, or swelling of the face or throat — call 999 immediately if anaphylaxis is suspected

For urgent concerns that are not an emergency, you can also contact NHS 111 (online at 111.nhs.uk or by telephone).

As retatrutide is an investigational medicine, any adverse events must be reported through your trial's reporting pathway in line with the study protocol. In addition, suspected side effects can be reported directly to the MHRA via the Yellow Card scheme at yellowcard.mhra.gov.uk or through the Yellow Card app. Reporting helps the MHRA monitor the safety of medicines and medical devices in the UK.

Storing Retatrutide and Disposing of Used Equipment

Store retatrutide refrigerated at 2°C to 8°C, never freeze it, and dispose of all used needles immediately in an approved sharps bin, never in household waste.

Correct storage of retatrutide is essential to maintain the stability and efficacy of the medication. As an investigational peptide-based injectable, retatrutide must be stored strictly in accordance with the IMP label and clinical trial protocol provided to you by the trial team. Do not rely on storage guidance from other GLP-1 or similar products, as conditions may differ.

General storage principles for injectable biologics typically include:

• Refrigerated storage at 2°C to 8°C when not in use

• Do not freeze — if the medication has been accidentally frozen, do not use it and contact your trial team

• Protect from direct light — store in the original packaging until ready to use

• In-use storage duration and temperature limits — follow the specific instructions on your IMP label or as directed by your trial team; do not assume these are the same as for licensed products

Always check the expiry date before use and never administer medication that has passed this date or shows signs of degradation (e.g., cloudiness, discolouration, or damaged packaging). Keep all medicines out of the sight and reach of children. Any unused investigational product should be returned to the trial team as instructed by the study protocol.

The safe disposal of sharps is a legal and public health responsibility in the UK. Used needles and syringes must never be placed in household recycling or general waste bins. Instead:

• Place all used needles immediately into an approved sharps bin (yellow-lidded container), which your trial team or GP surgery may be able to supply

• When the sharps bin is three-quarters full, seal it and arrange collection or disposal through your local council or NHS Board — arrangements vary by region, so check your local authority's website or contact your GP surgery or community pharmacy to confirm what services are available in your area

• Do not attempt to recap or bend used needles

For region-specific sharps disposal guidance, visit your local council website or speak to your GP surgery or community pharmacy.

Frequently Asked Questions